Literature DB >> 16426972

Light-activated destruction of cancer cell nuclei by platinum diazide complexes.

Patrick J Bednarski1, Renate Grünert, Michael Zielzki, Anja Wellner, Fiona S Mackay, Peter J Sadler.   

Abstract

A possible way to avoid dose-limiting side effects of platinum anticancer drugs is to employ light to cause photochemical changes in nontoxic platinum prodrugs that release active antitumor agents. This strategy could be used in the treatment of localized cancers accessible to irradiation (e.g., bladder, lung, esophagus, and skin). We report here that nontoxic photolabile diam(m)ino platinum(IV) diazido complexes inhibit the growth of human bladder cancer cells upon irradiation with light, and are non-crossresistant to cisplatin. Their rate of photolysis closely parallels that of DNA platination, indicating that the photolysis products interact directly, and rapidly, with DNA. Photoactivation results in a dramatic shrinking of the cancer cells, loss of adhesion, packing of nuclear material, and eventual disintegration of their nuclei, indicating a different mechanism of action from cisplatin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426972     DOI: 10.1016/j.chembiol.2005.10.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  15 in total

Review 1.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Photoactivation of trans diamine platinum complexes in aqueous solution and effect on reactivity towards nucleotides.

Authors:  Leticia Cubo; Ana M Pizarro; Adoración Gómez Quiroga; Luca Salassa; Carmen Navarro-Ranninger; Peter J Sadler
Journal:  J Inorg Biochem       Date:  2010-04-28       Impact factor: 4.155

Review 4.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

5.  Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanism.

Authors:  Aron F Westendorf; Julie A Woods; Katharina Korpis; Nicola J Farrer; Luca Salassa; Kim Robinson; Virginia Appleyard; Karen Murray; Renate Grünert; Alastair M Thompson; Peter J Sadler; Patrick J Bednarski
Journal:  Mol Cancer Ther       Date:  2012-06-18       Impact factor: 6.261

6.  Photoinduced reactions of cis,trans,cis-[Pt(IV)(N3)2(OH)2(NH3)2) with 1-methylimidazole.

Authors:  Hazel I A Phillips; Luca Ronconi; Peter J Sadler
Journal:  Chemistry       Date:  2009       Impact factor: 5.236

Review 7.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

8.  A potent cytotoxic photoactivated platinum complex.

Authors:  Fiona S Mackay; Julie A Woods; Pavla Heringová; Jana Kaspárková; Ana M Pizarro; Stephen A Moggach; Simon Parsons; Viktor Brabec; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-19       Impact factor: 11.205

9.  Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Adv Inorg Chem       Date:  2009-07-07       Impact factor: 3.282

Review 10.  New trends for metal complexes with anticancer activity.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Curr Opin Chem Biol       Date:  2008-01-25       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.